Jane Street Group, LLC Incyte Corp Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Incyte Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 146,748 shares of INCY stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

146,748

Previous 1,490,359 90.15%

Holding current value

$10.1 Million

Previous $90.3 Million 89.26%

% of portfolio

0.0%

Previous 0.1%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $77 Million - $92.2 Million	-1,343,611 Reduced 90.15%	146,748 $9.7 Million
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $65.1 Million - $81 Million	1,271,135 Added 579.83%	1,490,359 $90.3 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $9.56 Million - $11.3 Million	-169,028 Reduced 43.54%	219,224 $12.5 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $16.3 Million - $20 Million	311,986 Added 409.08%	388,252 $24.4 Million
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $2.3 Million - $2.62 Million	39,812 Added 109.21%	76,266 $4.41 Million
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $2.1 Million - $2.6 Million	-34,412 Reduced 48.56%	36,454 $2.27 Million
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $2.1 Million - $2.57 Million	-29,881 Reduced 29.66%	70,866 $5.12 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $1.39 Million - $1.74 Million	-20,714 Reduced 17.05%	100,747 $8.09 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $69,158 - $86,588	1,045 Added 0.87%	121,461 $8.1 Million
Q2 2022 Aug 16, 2022	BUY	$66.18 - $83.18 $1.79 Million - $2.26 Million	27,113 Added 29.06%	120,416 $9.15 Million
Q1 2022 May 17, 2022	BUY	$66.02 - $79.71 $132,832 - $160,376	2,012 Added 2.2%	93,303 $7.41 Million
Q4 2021 Feb 15, 2022	BUY	$63.34 - $74.11 $1.09 Million - $1.27 Million	17,179 Added 23.18%	91,291 $6.7 Million
Q3 2021 Nov 16, 2021	SELL	$68.67 - $84.02 $709,086 - $867,590	-10,326 Reduced 12.23%	74,112 $5.1 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $3.57 Million - $3.91 Million	44,694 Added 112.45%	84,438 $7.1 Million
Q1 2021 May 18, 2021	BUY	$76.02 - $100.5 $2.16 Million - $2.86 Million	28,443 Added 251.69%	39,744 $3.23 Million
Q4 2020 Feb 17, 2021	BUY	$80.74 - $97.7 $365,267 - $441,994	4,524 Added 66.76%	11,301 $983,000
Q3 2020 Nov 17, 2020	BUY	$85.07 - $109.69 $147,086 - $189,654	1,729 Added 34.25%	6,777 $608,000
Q2 2020 Aug 17, 2020	SELL	$74.18 - $108.93 $1.2 Million - $1.77 Million	-16,207 Reduced 76.25%	5,048 $525,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $1.27 Million - $1.73 Million	-20,109 Reduced 48.61%	21,255 $1.56 Million
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $2.28 Million - $2.99 Million	31,268 Added 309.71%	41,364 $3.61 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $742,836 - $882,590	-10,201 Reduced 50.26%	10,096 $749,000
Q2 2019 Aug 15, 2019	SELL	$73.52 - $88.7 $666,311 - $803,888	-9,063 Reduced 30.87%	20,297 $1.72 Million
Q1 2019 May 16, 2019	SELL	$63.56 - $88.17 $171,993 - $238,588	-2,706 Reduced 8.44%	29,360 $2.53 Million
Q4 2018 Feb 15, 2019	BUY	$58.5 - $69.94 $926,523 - $1.11 Million	15,838 Added 97.6%	32,066 $2.04 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $222,670 - $267,673	3,606 Added 28.57%	16,228 $1.12 Million
Q2 2018 Aug 15, 2018	SELL	$60.85 - $83.98 $783,382 - $1.08 Million	-12,874 Reduced 50.49%	12,622 $846,000
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $2.47 Million - $3 Million	-29,753 Reduced 53.85%	25,496 $2.13 Million
Q4 2017 Feb 15, 2018	BUY	$93.56 - $116.6 $2.43 Million - $3.03 Million	25,991 Added 88.83%	55,249 $5.23 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $3.19 Million - $4.05 Million	29,258	29,258 $3.42 Million

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Incyte Corp Transaction History